Key statistics
On Friday, ELEVAI Labs Inc (ELAB:NAQ) closed at 0.0201, 24.84% above the 52 week low of 0.0161 set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0186 |
---|---|
High | 0.021 |
Low | 0.0177 |
Bid | 0.0172 |
Offer | 0.0174 |
Previous close | 0.0202 |
Average volume | 443.12m |
---|---|
Shares outstanding | 517.66m |
Free float | 474.26m |
P/E (TTM) | -- |
Market cap | 10.40m USD |
EPS (TTM) | -0.2924 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
- Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
- CORRECTION - Elevai Labs Inc.
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
- Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
- REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
More ▼